Addex Therapeutics Ltd
ADXN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.02 | -0.04 | 0.05 |
| FCF Yield | -7.55% | -7.80% | -11.26% | -0.45% |
| EV / EBITDA | -3.12 | -1.59 | -1.72 | -1.61 |
| Quality | ||||
| ROIC | -11.30% | -9.95% | -7.19% | -4.51% |
| Gross Margin | 100.00% | -544.55% | 0.00% | 100.00% |
| Cash Conversion Ratio | 0.34 | 0.23 | 0.41 | 0.02 |
| Growth | ||||
| Revenue 3-Year CAGR | -67.94% | -64.97% | -53.40% | -34.26% |
| Free Cash Flow Growth | -27.00% | 29.88% | -2,441.63% | 94.11% |
| Safety | ||||
| Net Debt / EBITDA | 1.37 | 1.16 | 1.89 | 2.83 |
| Interest Coverage | -1,474.95 | -884.07 | -1,106.32 | -299.88 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 155.17 | -150.60 | 0.00 | 925.84 |